Targeting Specific Tau Proteins for Alzheimer's Disease
Epitope-Specific Targeting of Tau Aggregates
This project aims to develop more effective antibody treatments for Alzheimer's disease by understanding how different antibodies interact with harmful tau proteins.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11093491 on NIH RePORTER |
What this research studies
Many new treatments for Alzheimer's disease are currently being tested, focusing on antibodies that target harmful tau proteins in the brain. Our work explores why small differences in how these antibodies attach to tau can significantly change their effectiveness. We are also looking into which type of antibody is best for clearing tau and preventing its toxic effects, considering how well they can be taken up by brain cells. The goal is to find the most powerful ways to remove tau, both inside and outside brain cells, to better fight Alzheimer's.
Who could benefit from this research
Good fit: This foundational work is not directly recruiting patients, but future clinical trials stemming from this research would likely seek individuals diagnosed with Alzheimer's disease dementia.
Not a fit: Patients who do not have Alzheimer's disease dementia would not directly benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more effective antibody treatments that better clear harmful tau proteins in patients with Alzheimer's disease.
How similar studies have performed: Similar antibody-based approaches targeting tau proteins are already in clinical trials, suggesting a promising direction for this type of therapy.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Sigurdsson, Einar M — New York University School of Medicine
- Study coordinator: Sigurdsson, Einar M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.